Focus: AlterG develops anti-gravity treadmill technology and rehabilitation devices, operating in the medical device/biotechnology intersection with a focus on gait and mobility applications. The company is public and based in Fremont, CA since 2005.
Profile data last refreshed 3d ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow AlterG to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship product enabling unweighting therapy for orthopedic and neurological recovery.
Help build intelligence for AlterG
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from AlterG's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Lifeward scoops US$20M after completing Oratech Pharma takeover - Mugglehead Investment Magazine
Lifeward scoops US$20M after completing Oratech Pharma takeover Mugglehead Investment Magazine
8-K Filing: ORAMED PHARMACEUTICALS INC. (ORMP) (CIK 0001176309) — PRESS RELEASE DATED JANUARY 13, 2026
PRESS RELEASE DATED JANUARY 13, 2026
Oramed and Lifeward Announce Strategic Transaction - PR Newswire
Oramed and Lifeward Announce Strategic Transaction PR Newswire
8-K Filing: Lifeward Ltd. (LFWD) (CIK 0001607962) — EXHIBIT 99.1
EXHIBIT 99.1
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo